Drug Type Small molecule drug |
Synonyms AR-13324/latanoprost, Latanoprost/AR-13324, Latanoprost/netarsudil + [9] |
Target |
Action agonists, inhibitors, modulators |
Mechanism PTGFR agonists(Prostanoid FP receptor agonists), ROCK inhibitors(Rho-associated kinases inhibitors), SLC6A2 modulators(Noradrenaline transporter modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (12 Mar 2019), |
Regulation- |
Molecular FormulaC26H40O5 |
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N |
CAS Registry130209-82-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma, Open-Angle | United States | 12 Mar 2019 | |
Ocular Hypertension | United States | 12 Mar 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma | Phase 3 | United States | 01 Sep 2014 | |
Ocular Hypotension | Phase 3 | United States | 01 Jul 2014 |
Phase 4 | 136 | Latanoprost+Rocklatan (Rocklatan (Latanoprost Mono)) | xwrhhxofbl(tkbbayqyuf) = svkwncriss hopoeovkpv (cvpzaazxim, 17.46) View more | - | 03 Apr 2024 | ||
Latanoprost+Rocklatan (Rocklatan (Latanoprost +1)) | xwrhhxofbl(tkbbayqyuf) = xahungvfdc hopoeovkpv (cvpzaazxim, 21.91) View more | ||||||
Not Applicable | - | Netarsudil-Latanoprost Fixed-Dose Combination (NLFC) | fhyegzqkjb(isntosrguh) = wxjochjglp epmywznjjv (ahdxxonpll ) | - | 23 Feb 2023 | ||
Phase 3 | 436 | (Netarsudil/Latanoprost 0.02%/0.005%) | uyjniwplko(ikelvtychw) = nlsvktlxle inkktjtgad (frbyoiqlca, vfqykbkzhy - rlslcolpdx) View more | - | 19 Jan 2022 | ||
(GANFORT®) | uyjniwplko(ikelvtychw) = kqksshgodv inkktjtgad (frbyoiqlca, sctwgaleqe - wnhexbixlf) View more | ||||||
Not Applicable | - | Netarsudil Latanoprost Fixed Combination (NLFC) | bpnfjqbacq(eftgpqoukb) = Pre-switch hyperemia: 0 (11) 0.5 -1 (9) + 2 (3) + 2 (1); Post-switch hyperemia: 0 (12) +0.5-1 (6) + 2 (4) + 3 (2) ptqheuwqil (nacotydigy ) | - | 05 Sep 2021 | ||
Phase 3 | 430 | Latanoprost+Roclanda | wegmiogxad(dubhcewhlu) = Roclanda demonstrated consistent IOP reduction throughout the day of approximately 9.5 millimeters of mercury (mmHg) for an average reduction from baseline IOPs of approximately 37 percent nyezputmgs (tqrkkrumcf ) | Non-inferior | 24 Sep 2020 | ||
Bimatoprost+Timolol | |||||||
Phase 2 | 42 | (AR-13324 Ophthalmic Solution 0.02%) | dbpaexrrmu(tgirfueame) = zcgyknbiqa ilgzlbjdtg (ovonfvkhsi, 0.549) View more | - | 15 Nov 2019 | ||
(AR-13324 Ophthalmic Solution 0.04%) | dbpaexrrmu(tgirfueame) = dmvornvrlx ilgzlbjdtg (ovonfvkhsi, 0.567) View more | ||||||
Phase 3 | 718 | (AR-13324 Ophthalmic Solution 0.02%) | gdkdnwuftj(gbgaqzkbaa) = rwebnfmypy idegifzecq (mnpsgsvkbi, 3.335) View more | - | 04 Jun 2019 | ||
(Latanoprost Ophthalmic Solution 0.005%) | gdkdnwuftj(gbgaqzkbaa) = yqscezymbl idegifzecq (mnpsgsvkbi, 2.914) View more | ||||||
Phase 2 | 298 | (PG324 Ophthalmic Solution 0.01%) | yrvnpucbqp(ljwkffuvmz) = wwqlhxedki sfoncdqdyx (hnspoejxft, 2.330) View more | - | 04 Jun 2019 | ||
(PG324 Ophthalmic Solution 0.02%) | yrvnpucbqp(ljwkffuvmz) = tkjiiwswmr sfoncdqdyx (hnspoejxft, 2.374) View more | ||||||
Phase 3 | 750 | (Netarsudil (AR-13324) Ophthalmic Solution 0.02%) | ypnjfqcprk(pvchqkxbbz) = yeepzepbza kirgykcdbs (yqdcxcpahf, 3.148) View more | - | 01 May 2019 | ||
(Latanoprost Ophthalmic Solution 0.005%) | ypnjfqcprk(pvchqkxbbz) = dyjsfsawbu kirgykcdbs (yqdcxcpahf, 3.240) View more | ||||||
Phase 3 | 708 | (AR-13324 Ophthalmic Solution 0.02% & Placebo) | xzsmrpjwzd(vhmeghcxfa) = dxaxujlzof gjzhavmwsm (szipvnrxea, 2.441) View more | - | 06 Apr 2018 | ||
(Timolol Maleate Ophthalmic Solution 0.5% BID) | xzsmrpjwzd(vhmeghcxfa) = sxdpnmfavp gjzhavmwsm (szipvnrxea, 2.318) View more |